Evidence map›Paper›PMID 23050947›Full record

ReviewJournal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research2012

Connecting the dots: artificial antigen presenting cell-mediated modulation of natural killer T cells.

Wenji Sun, Priyanka B Subrahmanyam, James E East, Tonya J Webb

Open access · greenAbstract readReview
In one paragraph

Review in Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.8field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. New applications of nanotechnology for neuroimaging.AJNR. American journal of neuroradiology · 2014
    Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Wenji SunDepartment of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Priyanka B Subrahmanyam
James E East
Tonya J Webb
University of Maryland, Baltimore · US

Funding

UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTERSUPPORT GRANTP30CA134274 · NCI · UNIVERSITY OF MARYLAND BALTIMORE · PI FEYRUZ VIRGILIA RASSOOL · 2008 to 2026
$51.0M
Training Grant in Cancer BiologyT32CA154274 · NCI · UNIVERSITY OF MARYLAND BALTIMORE · PI Toni M Antalis, CURT I CIVIN · 2011 to 2026
$6.8M
aAPC-Mediated NKT cell Modulation to Enhance Cancer ImmunotherapyK01CA131487 · NCI · UNIVERSITY OF MARYLAND BALTIMORE · PI WEBB, TONYA J. · 2008 to 2012
$584k
Restoring NKT cell function: a novel immunotherapeutic strategy for Breast CancerR21CA162273 · NCI · UNIVERSITY OF MARYLAND BALTIMORE · PI WEBB, TONYA J. · 2011 to 2012
$367k
Altered cellular bioenergetics influences NKT cell mediated responses to LymphomaR21CA162277 · NCI · UNIVERSITY OF MARYLAND BALTIMORE · PI WEBB, TONYA J. · 2011 to 2012
$359k
NCI NIH HHS K01 CA131487NCI NIH HHS P30 CA134274NCI NIH HHS R21 CA162273NCI NIH HHS R21 CA162277NCI NIH HHS T32 CA154274
6 · The paper itself

Abstract

Natural killer T (NKT) cells constitute an important subset of T cells that can both directly and indirectly mediate antitumor immunity. However, we and others have reported that cancer patients have a reduction in both NKT cell number and function. NKT cells can be stimulated and expanded with α-GalCer and cytokines and these expanded NKT cells retain their phenotype, remain responsive to antigenic stimulation, and display cytotoxic function against tumor cell lines. These data strongly favor the use of ex vivo expanded NKT cells in adoptive immunotherapy. NKT cell based-immunotherapy has been limited by the use of autologous antigen-presenting cells, which can vary substantially in their quantity and quality. A standardized system that relies on artificial antigen-presenting cells (aAPCs) could produce the stimulating effects of dendritic cell (DC) without the pitfalls of allo- or xenogeneic cells. In this review, we discuss the progress that has been made using CD1d-based aAPC and how this acellular antigen presenting system can be used in the future to enhance our understanding of NKT cell biology and to develop NKT cell-specific adoptive immunotherapeutic strategies.

Indexed as

Antigen PresentationImmunotherapy, AdoptiveAntigen-Presenting CellsAntigens, CD1dCell Line, TumorCytokinesGalactosylceramidesHumansLymphocyte ActivationLymphocyte CountNatural Killer T-CellsNeoplasmsalpha-galactosylceramideAntigens, CD1dCytokinesGalactosylceramides

Identifiers

PMID23050947
PMCPMC3493043
OpenAlexW2034626255

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.